Advanced peptide or injection for precise dosing.
Certified Facility
Pithampur, Sector-1
Medikrebs Formulations Private Limited is establishing a state-of-the-art peptide or injectible drug product manufacturing facility in Pithampur, Madhya Pradesh, strengthening Central India’s injectable manufacturing capacity.
Promoted by Mr. Harshit Agnihotri and Mr. Prakash Sharma, the facility is designed to comply with Schedule M, WHO-GMP, and EU-GMP standards, focusing on Pre-Filled Syringe (PFS) and Pen-Device delivery systems for domestic and global markets.
World-class infrastructure designed for precision, quality, and regulatory compliance
Dedicated PFS manufacturing line with 30,000 units/day capacity featuring sterile formulation, aseptic filling, stoppering, and sealing with comprehensive in-process controls.
Advanced cleanroom classification and validated aseptic processing systems ensuring contamination control and product sterility throughout the manufacturing process.
Specialized cartridge and pen-device filling line supporting sterile filling, device assembly, labeling, and packaging for patient-centric delivery systems.
Comprehensive QMS with data integrity-compliant documentation, validated processes, and continuous quality monitoring aligned with international standards.
Facility designed to meet Schedule M, WHO-GMP, and EU-GMP requirements, positioned for regulated market supply and international inspections.
Centrally positioned in Pithampur with proximity to major distribution hubs, excellent connectivity, and access to skilled technical manpower.
Advanced GLP-1 receptor agonist therapies for diabetes and obesity management
Established GLP-1 analog peptide or injectible widely prescribed for diabetes and weight management therapies. Well-documented safety and efficacy profile with consistent demand across regulated and emerging markets.
6 mg/mL solution in 3 mL pre-filled pen
Advanced GLP-1 receptor agonist therapies for diabetes and obesity management
Advanced GLP-1 receptor agonist for Type-2 Diabetes Mellitus and obesity management. Demonstrated clinical efficacy in glycemic control, cardiovascular risk reduction, and sustained weight management.
Established GLP-1 analog peptide widely prescribed for diabetes and weight management therapies. Well-documented safety and efficacy profile with consistent demand across regulated and emerging markets.
6 mg/mL solution in 3 mL pre-filled pen
Our facility adheres to the highest national and international pharmaceutical regulatory standards
Drugs & Cosmetics Rules, India
World Health Organization Guidelines
European Union Standards
Quality Management Systems
For inquiries related to peptide or injectable drug product manufacturing,
Pre-Filled Syringe (PFS) and Pen-Device filling capabilities, or future CDMO opportunities, please connect with us.
Our team will respond to your message at the earliest.
